These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20408553)

  • 1. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
    Arhancet GB; Woodard SS; Dietz JD; Garland DJ; Wagner GM; Iyanar K; Collins JT; Blinn JR; Numann RE; Hu X; Huang HC
    J Med Chem; 2010 May; 53(10):4300-4. PubMed ID: 20408553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
    Kosaka H; Hirayama K; Yoda N; Sasaki K; Kitayama T; Kusaka H; Matsubara M
    Eur J Pharmacol; 2010 Jun; 635(1-3):49-55. PubMed ID: 20307534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.
    Dietz JD; Du S; Bolten CW; Payne MA; Xia C; Blinn JR; Funder JW; Hu X
    Hypertension; 2008 Mar; 51(3):742-8. PubMed ID: 18250364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.
    Fagart J; Hillisch A; Huyet J; Bärfacker L; Fay M; Pleiss U; Pook E; Schäfer S; Rafestin-Oblin ME; Kolkhof P
    J Biol Chem; 2010 Sep; 285(39):29932-40. PubMed ID: 20650892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
    Rogerson FM; Yao Y; Smith BJ; Fuller PJ
    Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.
    Kolkhof P; Borden SA
    Mol Cell Endocrinol; 2012 Mar; 350(2):310-7. PubMed ID: 21771637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers.
    Teleb M; Zhang FX; Farghaly AM; Aboul Wafa OM; Fronczek FR; Zamponi GW; Fahmy H
    Eur J Med Chem; 2017 Jul; 134():52-61. PubMed ID: 28399450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of spirolactone recognition by the mineralocorticoid receptor.
    Huyet J; Pinon GM; Fay MR; Fagart J; Rafestin-Oblin ME
    Mol Pharmacol; 2007 Sep; 72(3):563-71. PubMed ID: 17569793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
    Arhancet GB; Woodard SS; Iyanar K; Case BL; Woerndle R; Dietz JD; Garland DJ; Collins JT; Payne MA; Blinn JR; Pomposiello SI; Hu X; Heron MI; Huang HC; Lee LF
    J Med Chem; 2010 Aug; 53(16):5970-8. PubMed ID: 20672820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
    Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
    Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
    Baxter JD; Funder JW; Apriletti JW; Webb P
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):151-65. PubMed ID: 15134814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the 1,4-dihydropyridines binding interactions in the L-type Ca2+ channel: model construction and docking calculations.
    Cosconati S; Marinelli L; Lavecchia A; Novellino E
    J Med Chem; 2007 Apr; 50(7):1504-13. PubMed ID: 17335186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling.
    Ogihara T; Kano T; Kakinuma C
    Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
    Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
    FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels.
    Yamamoto T; Niwa S; Ohno S; Tokumasu M; Masuzawa Y; Nakanishi C; Nakajo A; Onishi T; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4813-6. PubMed ID: 18684623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Permanently charged chiral 1,4-dihydropyridines: molecular probes of L-type calcium channels. Synthesis and pharmacological characterization of methyl(omega-trimethylalkylammonium) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate iodide, calcium channel antagonists.
    Peri R; Padmanabhan S; Rutledge A; Singh S; Triggle DJ
    J Med Chem; 2000 Jul; 43(15):2906-14. PubMed ID: 10956198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5-S6 linker of L-type Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca2+ channel agonists.
    Yamaguchi S; Zhorov BS; Yoshioka K; Nagao T; Ichijo H; Adachi-Akahane S
    Mol Pharmacol; 2003 Aug; 64(2):235-48. PubMed ID: 12869628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential sensitivities of CaV1.2 IIS5-S6 mutants to 1,4-dihydropyridine analogs.
    Hui K; Kwok TC; Kostelecki W; Leen J; Roy PJ; Feng ZP
    Eur J Pharmacol; 2009 Jan; 602(2-3):255-61. PubMed ID: 19068212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators.
    Rovnyak GC; Kimball SD; Beyer B; Cucinotta G; DiMarco JD; Gougoutas J; Hedberg A; Malley M; McCarthy JP; Zhang R
    J Med Chem; 1995 Jan; 38(1):119-29. PubMed ID: 7837222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.